197369-10-1

Basic information

• Product Name: 2-(4-methyl-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester
• Synonyms: 2-(4-methyl-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester
• CAS NO: 197369-10-1
• Molecular Weight: 312.322
• Mol File: 197369-10-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(4-methyl-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methyl-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester(197369-10-1)
• EPA Substance Registry System: 2-(4-methyl-benzoyl)-4,5-(methylenedioxy)-phenylacetic acid methyl ester(197369-10-1)

Safety Data

• Hazardous Substances Data: 197369-10-1(Hazardous Substances Data)

Upstream product

• 326-59-0 benzo[1,3]dioxol-5-yl-acetic acid methyl ester 
• 874-60-2 4-methyl-benzoyl chloride 

Relevant articles and documents

Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereof

The invention relates to a method for the preparation of compound of formula (1). The invention further relates to the previously unknown compounds of formulas (5 and 6) as intermediates in the production of benzodiazepines of formula (1).

SUBSTITUTED 2,3-BENZODIAZEPIN-4-ONES AND THE USE THEREOF

The invention relates to substituted 2,3-benzodiazepin-4-ones which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition enhancers. The invention also is directed to the process for the preparation of the substituted 2,3-benzodiazepin-4-ones.